The annual nos are updated after the annual reports are published - so its happening as the reports are getting published.
Posts tagged Value Pickr
Muthoot Finance: Undervalued quality stock on a turnaround? (09-09-2015)
That makes sense, and its reflecting in NPA increase of manappuram for last 5 years. However gross NPA is still 1% of total assets which is noway near alarming levels and doesnt alone justify such low P/B valuations. There is more to such low valuations than risky assets, and may be regulatory uncertainty is keeping things low. For eg: Gold monetization scheme will hit their business, so certainly headwinds facing gold finance business.
Disc: Invested at CMP.
Screener.in: The destination for Intelligent Screening & Reporting in India (09-09-2015)
Hi,
Siyaram Silk Mills. The operating profit figures are not correct.
Screener.in: The destination for Intelligent Screening & Reporting in India (09-09-2015)
Hi,
The export to excel button seems to be missing.. have i done something incorrectly?
Has it been removed? I would attach an image, but I don't see an attach option.
Please help!
Thanks,
Sanjay
Wednesday, Sep 09, 2015
Syngene International IPO – Views invited (09-09-2015)
@Mahesh Would love to hear your views on what would be a fair P/E for Syngene
Syngene International IPO – Views invited (09-09-2015)
If venturing into commercial manufacturing is successful, then 5 years post start of commercial manufacturing, opportunity could be huge for this company.....It will not be right to put any number to it but one can gauge the size from the fact that industry itself is likely to grow in double digits in foreseeable future.
Getting associated with an innovator for NME takes atleast 8-10 years of trust building....forget here the high quality standards you need to maintain and multiple inspections that you need to clear not only from regulatory authorities but also from the innovator.
Just wait for Sep.'15 shareholding vivek, its not far away.....we might find good institutional holding in that shareholding disclosure. With rgds. to Columbia Pacific, you can find its details on https://www.columbiathreadneedleus.com ....its heartening to see the fund investing more than 3 % of its corpus in Syngene......the fund seems to be a long term investor with many bluechip names in its holding....
Rgds.
Vakrangee (09-09-2015)
Already got nod for 100% FDI in white label ATMs, whats the impact with Vakrangee
Thanks
Syngene International IPO – Views invited (09-09-2015)
@Mahesh I like both Syngene and Suven - both would be among my top 6-7 bets (if I was forced to take 6-7 bets). With Syngene, what I like more is that they are involved from discovery stage for many molecules. With Suven, what I like is that they have mind-blowing margins for CRM (ex their in-house research); inspite of their cash guzzling research, and assuming none of this fructifies, I still believe Suven is a very good business. If one wants to take the inhouse research into consideration for valuation, then I agree - Suven has no place in a concentrated portfolio. Syngene I feel is slightly overvalued at CMP, Suven is fairly valued.
@Vivek_6954 As Mahesh has mentioned, the 3 phases of clinical trials take 6-8 years, not even considering the discovery phase. So if a company enters this business today and if they get small contracts, the partner might see that they are doing good work after few years, but to build trust about privacy with the partner, and particularly in the industry would take a longer time. The other aspect is one would need to start with smaller number of scientists and increase as one gets more contracts. One can poach a handful of experienced scientists here-there but not a team as large as Syngene.
Q for scuttlebutt: How satisfied are the scientists at Syngene/Suven with their careers?
Discl.: No holding in Syngene or Suven. Recently sold off stake in Suven on realizing mistake that there is no MoS.
Muthoot Finance: Undervalued quality stock on a turnaround? (09-09-2015)
Your book value erodes - when you engage in risky lending that ends up in capital losses.. Typically, if you have a history of riskier lending, then the market values you at lower P/BV....
Syngene International IPO – Views invited (09-09-2015)
Mahesh,
Thanks for explaining the Syngene story in a lucid way.
Whats your take on Opp size & ROCE for the co?Will it be in an ever increasing model?
Are entry barriers so high that it will take a long time for competitors to creep in?
Any update on instl holding in the co ? who is this columbia pacific which bt 18 lacs shares on listing day?